MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.
暂无分享,去创建一个
S. Armstrong | A. Letai | V. Seshan | G. Sauvageau | M. Gonen | S. Ficarro | A. Melnick | J. Marto | A. Kentsis | R. Koche | R. Levine | M. Tallman | E. de Stanchina | A. Krivtsov | Vincent-Philippe Lavallée | J. Hébert | E. Paietta | P. Romanienko | P. Bhola | G. Pouliot | B. Spitzer | C. Reed | P. Cifani | Christina Y. Yim | F. Brown | C. McCarthy | Willie H. Mark | S. Takao | Crystal A Stutzke | E. Still | S. Gunasekera | Conor O’Donnell | Eric R. Still | C. Yim | Fiona C. Brown | Sumiko Takao | S. Armstrong | R. Levine | Peter Romanienko
[1] N. López-Bigas,et al. HDAC7 Is a Repressor of Myeloid Genes Whose Downregulation Is Required for Transdifferentiation of Pre-B Cells into Macrophages , 2013, PLoS genetics.
[2] Yi Zhang,et al. multiplierz: an extensible API based desktop environment for proteomics data analysis , 2009, BMC Bioinformatics.
[3] J. Dick,et al. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity , 2004, Nature Immunology.
[4] E. Cho,et al. Menin represses JunD transcriptional activity in protein kinase Cθ-mediated Nur77 expression , 2005, Experimental & Molecular Medicine.
[5] A. Letai,et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. , 2014, Cancer discovery.
[6] Christopher A. Miller,et al. Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. , 2015, JAMA.
[7] M. Imoto,et al. GSK-3β Directly Phosphorylates and Activates MARK2/PAR-1* , 2005, Journal of Biological Chemistry.
[8] A. D. Dei Tos,et al. The co-existence of transcriptional activator and transcriptional repressor MEF2 complexes influences tumor aggressiveness , 2017, PLoS genetics.
[9] E. Lam,et al. Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells , 2005, Oncogene.
[10] M. Marra,et al. MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation , 2015, Nature Communications.
[11] S. Ficarro,et al. Magnetic bead processor for rapid evaluation and optimization of parameters for phosphopeptide enrichment. , 2009, Analytical chemistry.
[12] A. Kentsis,et al. High Sensitivity Quantitative Proteomics Using Automated Multidimensional Nano-flow Chromatography and Accumulated Ion Monitoring on Quadrupole-Orbitrap-Linear Ion Trap Mass Spectrometer* , 2017, Molecular & Cellular Proteomics.
[13] R. Pieters,et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. , 2011, Blood.
[14] D. Jd,et al. Pediatric AML: From Biology to Clinical Management , 2015 .
[15] Mark D'Ascenzo,et al. 8‐Plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease , 2007, Proteomics.
[16] F. Sablitzky,et al. The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. , 2006, Blood.
[17] B. Nadal-Ginard,et al. Human myocyte-specific enhancer factor 2 comprises a group of tissue-restricted MADS box transcription factors. , 1992, Genes & development.
[18] P. Vyas,et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. , 2011, Cancer cell.
[19] T. Golub,et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9 , 2006, Nature.
[20] J. Dick,et al. Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia , 2005, Leukemia.
[21] S. Raimondi,et al. High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children’s Oncology Group , 2015, Journal of Hematology & Oncology.
[22] D. Small,et al. Lack of KIT or FMS internal tandem duplications but co-expression with ligands in AML. , 2004, Leukemia research.
[23] N. Copeland,et al. Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. , 2005, Blood.
[24] J. Downing,et al. Mouse models of human AML accurately predict chemotherapy response. , 2009, Genes & development.
[25] Cell Lines , 1992, Spermatogenesis.
[26] R. Pieters,et al. Characterization of a pediatric T-cell acute lymphoblastic leukemia patient with simultaneous LYL1 and LMO2 rearrangements , 2012, Haematologica.
[27] N. Gray,et al. Protected Amine Labels: A Versatile Molecular Scaffold for Multiplexed Nominal Mass and Sub-Da Isotopologue Quantitative Proteomic Reagents , 2014, Journal of The American Society for Mass Spectrometry.
[28] M. Cleary,et al. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. , 2006, Cancer cell.
[29] Bob Löwenberg,et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] John N. Hutchinson,et al. Phosphoproteomic profiling of mouse primary HSPCs reveals new regulators of HSPC mobilization. , 2016, Blood.
[31] R. Arceci,et al. Somatic characterization of pediatric acute myeloid leukemia using next-generation sequencing. , 2013, Seminars in hematology.
[32] Wolfgang Wurst,et al. Generation of targeted mouse mutants by embryo microinjection of TALENs. , 2014, Methods.
[33] B. Leber,et al. The sonic hedgehog factor Gli1 imparts drug resistance through inducible glucuronidation , 2014, Nature.
[34] H. Jäck,et al. Essential control of early B-cell development by Mef2 transcription factors. , 2016, Blood.
[35] Zhenguo Wu,et al. Myocyte Enhancer Factor 2 Acetylation by p300 Enhances Its DNA Binding Activity, Transcriptional Activity, and Myogenic Differentiation , 2005, Molecular and Cellular Biology.
[36] Patrick G. A. Pedrioli,et al. Phosphorylation of CRTC3 by the salt-inducible kinases controls the interconversion of classically activated and regulatory macrophages , 2012, Proceedings of the National Academy of Sciences.
[37] M. Hornsveld,et al. Restraining FOXO3-dependent transcriptional BMF activation underpins tumour growth and metastasis of E-cadherin-negative breast cancer , 2016, Cell Death and Differentiation.
[38] Jiahuai Han,et al. Regulation of the MEF2 Family of Transcription Factors by p38 , 1999, Molecular and Cellular Biology.
[39] M. Peng,et al. Toward a comprehensive characterization of a human cancer cell phosphoproteome. , 2013, Journal of proteome research.
[40] Guido Marcucci,et al. Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia , 2016, Nature Communications.
[41] C. Zwaan,et al. Pediatric AML: From Biology to Clinical Management , 2015, Journal of clinical medicine.
[42] N. Borcherding,et al. Stabilization of NF-κB-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia , 2018, Cell reports.
[43] K. Kemphues,et al. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed , 1995, Cell.
[44] G. Brittinger,et al. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. , 1998, Experimental hematology.
[45] E. Olson,et al. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Martín,et al. Mutational analysis of the DNA binding, dimerization, and transcriptional activation domains of MEF2C , 1996, Molecular and cellular biology.
[47] E. Olson,et al. MEF2: a calcium-dependent regulator of cell division, differentiation and death. , 2002, Trends in biochemical sciences.
[48] C. Brancolini,et al. The Control Operated by the Cell Cycle Machinery on MEF2 Stability Contributes to the Downregulation of CDKN1A and Entry into S Phase , 2015, Molecular and Cellular Biology.
[49] C. Bach,et al. Leukemogenic transformation by HOXA cluster genes. , 2010, Blood.
[50] S. T. Kim,et al. Menin represses JunD transcriptional activity in protein kinase C theta-mediated Nur77 expression. , 2005, Experimental & molecular medicine.
[51] R. Battini,et al. Phosphorylation-dependent degradation of MEF2C contributes to regulate G2/M transition , 2015, Cell cycle.
[52] Unnur Thorsteinsdottir,et al. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b , 1998, The EMBO journal.
[53] Jeffrey D. Zaremba,et al. Transcription factor MEF2C influences neural stem/progenitor cell differentiation and maturation in vivo , 2008, Proceedings of the National Academy of Sciences.
[54] M. Andreeff,et al. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang , 2016, Cancer biology & medicine.
[55] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[56] E. Olson,et al. The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. , 2008, Blood.
[57] Y. Ishihama,et al. Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase. , 2012, Journal of biochemistry.
[58] Francine E. Garrett-Bakelman,et al. DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling , 2016, Nature Medicine.
[59] Hongtao Yu,et al. Phosphorylation-facilitated sumoylation of MEF2C negatively regulates its transcriptional activity , 2006, BMC Biochemistry.
[60] B. Löwenberg,et al. Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[61] J. Byrd,et al. Genomics of primary chemoresistance and remission induction failure in paediatric and adult acute myeloid leukaemia , 2017, British journal of haematology.
[62] F. Camargo,et al. Regulation of lymphoid versus myeloid fate 'choice' by the transcription factor Mef2c , 2009, Nature Immunology.
[63] Andrew L. Kung,et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia , 2012, Nature Medicine.
[64] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[65] E. Olson,et al. Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C. , 2009, Blood.
[66] B. Chait,et al. Helicobacter pylori CagA Inhibits PAR1/MARK Family Kinases by Mimicking Host Substrates , 2009, Nature Structural &Molecular Biology.
[67] Andrew M Haidle,et al. MARK inhibitors: Declaring a No-Go decision on a chemical series based on extensive DMPK experimentation. , 2017, Bioorganic & medicinal chemistry letters.
[68] E. Mandelkow,et al. Glycogen Synthase Kinase (GSK) 3β Directly Phosphorylates Serine 212 in the Regulatory Loop and Inhibits Microtubule Affinity-regulating Kinase (MARK) 2* , 2008, Journal of Biological Chemistry.
[69] H. Drexler,et al. MEF2C is activated by multiple mechanisms in a subset of T-acute lymphoblastic leukemia cell lines , 2008, Leukemia.
[70] Joshua F. McMichael,et al. Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.
[71] P. Romanienko,et al. A Vector with a Single Promoter for In Vitro Transcription and Mammalian Cell Expression of CRISPR gRNAs , 2016, PloS one.
[72] S. Miyano,et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients , 2014, Leukemia.
[73] A. Villunger,et al. Bim and Bmf in tissue homeostasis and malignant disease , 2008, Oncogene.
[74] Nicola D. Roberts,et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.
[75] Jeffrey A. Magee,et al. Fetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations , 2016, eLife.
[76] W. Pierceall,et al. BH3 Profiling Discriminates Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia , 2013, Molecular Cancer Therapeutics.
[77] G. Brittinger,et al. In Acute Myeloid Leukemia only the Coexpression of at Least Two Proteins Including P-Glycoprotein, the Multidrug Resistance-Related Protein MRP, bcl-2, Mutant p53 and Heat-Shock Protein 27 is Predictive for the Response to Induction Chemotherapy , 1998 .
[78] G. Shulman,et al. Loss of the Par-1b/MARK2 polarity kinase leads to increased metabolic rate, decreased adiposity, and insulin hypersensitivity in vivo , 2007, Proceedings of the National Academy of Sciences.
[79] R. Schiestl,et al. MEF2C protects bone marrow B-lymphoid progenitors during stress haematopoiesis , 2016, Nature Communications.
[80] R. Levine,et al. Molecular therapy for acute myeloid leukaemia , 2016, Nature Reviews Clinical Oncology.
[81] C. Bucana,et al. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. , 1997, Science.
[82] T. Gulick,et al. Phosphorylation and Alternative Pre-mRNA Splicing Converge To Regulate Myocyte Enhancer Factor 2C Activity , 2004, Molecular and Cellular Biology.
[83] S. Armstrong,et al. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors , 2015, Genes & development.
[84] T. Hoang,et al. SCL, LMO1 and Notch1 Reprogram Thymocytes into Self-Renewing Cells , 2014, PLoS genetics.
[85] Richard Benton,et al. The Drosophila Homolog of C. elegans PAR-1 Organizes the Oocyte Cytoskeleton and Directs oskar mRNA Localization to the Posterior Pole , 2000, Cell.
[86] T. Graeber,et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. , 2011, Genes & development.
[87] M E Greenberg,et al. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. , 1999, Science.
[88] James T. Webber,et al. Online Nanoflow Multidimensional Fractionation for High Efficiency Phosphopeptide Analysis* , 2011, Molecular & Cellular Proteomics.
[89] Fatima Al-Shahrour,et al. In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. , 2013, Cancer cell.
[90] D. Muzny,et al. Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. , 2016, Cancer research.
[91] M. Imoto,et al. GSK-3beta directly phosphorylates and activates MARK2/PAR-1. , 2005, The Journal of biological chemistry.